208 related articles for article (PubMed ID: 6975654)
21. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
[TBL] [Abstract][Full Text] [Related]
22. The treatment of hairy cell leukemia (HCL) with pentostatin (2'-deoxycoformycin, dCF).
Spiers AS; Parekh SJ
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():173-5. PubMed ID: 2653498
[No Abstract] [Full Text] [Related]
23. Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine L5178Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2'-deoxycoformycin and deoxyadenosine in vitro.
Begleiter A; Pugh L; Israels LG; Johnston JB
Cancer Res; 1988 Jul; 48(14):3981-6. PubMed ID: 3260129
[TBL] [Abstract][Full Text] [Related]
24. 2'-deoxycoformycin (DCF) and 9-beta-D-arabinofuranosyladenine (Ara-A) in the treatment of refractory acute myelocytic leukemia.
Gray DP; Grever MR; Siaw MF; Coleman MS; Balcerzak SP
Cancer Treat Rep; 1982 Feb; 66(2):253-7. PubMed ID: 6976833
[TBL] [Abstract][Full Text] [Related]
25. ATP depletion as a consequence of adenosine deaminase inhibition in man.
Siaw MF; Mitchell BS; Koller CA; Coleman MS; Hutton JJ
Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6157-61. PubMed ID: 6969403
[TBL] [Abstract][Full Text] [Related]
26. Association of severe and fatal infections and treatment with pentostatin.
O'Dwyer PJ; Spiers AS; Marsoni S
Cancer Treat Rep; 1986 Sep; 70(9):1117-20. PubMed ID: 3488805
[TBL] [Abstract][Full Text] [Related]
27. Differential sensitivity of leukemic cells to growth inhibition by deoxyadenosine and deoxycoformycin.
Tanaka M; Kimura K
Tohoku J Exp Med; 1985 Dec; 147(4):331-41. PubMed ID: 3879563
[TBL] [Abstract][Full Text] [Related]
28. Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study.
Winick N; Buchanan GR; Murphy SB; Yu A; Boyett J
Med Pediatr Oncol; 1988; 16(5):327-32. PubMed ID: 3263563
[TBL] [Abstract][Full Text] [Related]
29. Alterations in erythrocyte adenine nucleotide pools resulting from 2'-deoxycoformycin therapy.
Koller CA; Mitchell BS
Cancer Res; 1983 Mar; 43(3):1409-14. PubMed ID: 6600652
[TBL] [Abstract][Full Text] [Related]
30. 2'-deoxycoformycin. A new anticancer agent.
Poster DS; Penta JS; Bruno S; Macdonald JS
Cancer Clin Trials; 1981; 4(2):209-13. PubMed ID: 7018725
[TBL] [Abstract][Full Text] [Related]
31. DNA strand breaks induced in human T-lymphocytes by the combination of deoxyadenosine and deoxycoformycin.
Brox L; Ng A; Pollock E; Belch A
Cancer Res; 1984 Mar; 44(3):934-7. PubMed ID: 6607110
[TBL] [Abstract][Full Text] [Related]
32. Low-dose deoxycoformycin in lymphoid malignancy.
Grever MR; Leiby JM; Kraut EH; Wilson HE; Neidhart JA; Wall RL; Balcerzak SP
J Clin Oncol; 1985 Sep; 3(9):1196-201. PubMed ID: 2993534
[TBL] [Abstract][Full Text] [Related]
33. Determinants of deoxyadenosine toxicity in hybrids between human T- and B- lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia.
Kurtzberg J; Hershfield MS
Cancer Res; 1985 Apr; 45(4):1579-86. PubMed ID: 3872167
[TBL] [Abstract][Full Text] [Related]
34. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Mitchell BS; Koller CA; Kelley WN
Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
[No Abstract] [Full Text] [Related]
35. Inhibition of RNA synthesis by deoxyadenosine plus deoxycoformycin in resting lymphocytes.
Matsumoto SS; Yu J; Yu AL
J Immunol; 1983 Dec; 131(6):2762-6. PubMed ID: 6196398
[TBL] [Abstract][Full Text] [Related]
36. Morphological changes in leukemic lymphoblasts and normal lymphocytes treated with deoxyadenosine plus deoxycoformycin.
Matsumoto SS; Yu AL; Yu J
Cancer Invest; 1985; 3(3):225-33. PubMed ID: 3873981
[TBL] [Abstract][Full Text] [Related]
37. Effects of (R)-deoxycoformycin (pentostatin) on intrauterine nucleoside catabolism and embryo viability in the pregnant mouse.
Knudsen TB; Winters RS; Otey SK; Blackburn MR; Airhart MJ; Church JK; Skalko RG
Teratology; 1992 Jan; 45(1):91-103. PubMed ID: 1731400
[TBL] [Abstract][Full Text] [Related]
38. Neurotoxicity of deoxycoformycin: effect of constant infusion on adenosine deaminase, adenosine, 2'-deoxyadenosine and monoamines in the mouse brain.
Helland S; Broch OJ; Ueland PM
Neuropharmacology; 1983 Jul; 22(7):915-7. PubMed ID: 6604884
[TBL] [Abstract][Full Text] [Related]
39. Relationship of 5'-nucleotidase activity and antileukemic effect in 2'-deoxycoformycin therapy.
Wortmann RL; Holcenberg J; Poplack DG
Cancer Treat Rep; 1982 Feb; 66(2):387-90. PubMed ID: 6275991
[No Abstract] [Full Text] [Related]
40. Dipyridamole enhancement of toxicity to L1210 cells by deoxyadenosine and deoxycoformycin combinations in vitro.
Kang GJ; Kimball AP
Cancer Res; 1984 Feb; 44(2):461-6. PubMed ID: 6362851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
